^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | iniparib (BSI 201) (PARP1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer
Excerpt:
This report describes the case of a patient with a germline BRCA2 mutation and an associated pancreatic cancer treated with iniparib (BSI-201), a PARP inhibitor, who demonstrated a complete pathologic response to this agent.
